Journals / Turkish Journal of Medical Sciences / 2015 / Cilt: 45 - Sayı: 1

Serum VEGF levels in gastric cancer patients: correlation with clinicopathological parameters

Pages
112–117
Publication Date
2015-03-15
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: In gastric cancer patients, serum VEGF levels may provide additional prognostic information for preoperative evaluation of invasion and tumor type.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:To evaluate the predictive role of the circulating levels of vascular endothelial growth factor (VEGF) in gastric cancer patients.
📊
Key Findings & Data:We measured serum VEGF levels of 30 patients aged between 34 and 83 years with gastric cancer and 30 patients without malignant pathology, operated on for benign pathologies, with ages ranging from 18 to 69.
💡
Conclusion & Impact:Conclusion: In gastric cancer patients, serum VEGF levels may provide additional prognostic information for preoperative evaluation of invasion and tumor type.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Gastric cancer · vascular endothelial growth factor · angiogenesis

Abstract

To evaluate the predictive role of the circulating levels of vascular endothelial growth factor (VEGF) in gastric cancer patients. Materials and methods: This study is a case-control study. We measured serum VEGF levels of 30 patients aged between 34 and 83 years with gastric cancer and 30 patients without malignant pathology, operated on for benign pathologies, with ages ranging from 18 to 69. Results: Serum levels of VEGF were correlated with the tumor type classification (signet cell adenocarcinoma) and the presence of adjacent tissue invasion. There was also a positive correlation between serum VEGF and carcinoembryonic antigen levels. Conclusion: In gastric cancer patients, serum VEGF levels may provide additional prognostic information for preoperative evaluation of invasion and tumor type.

Özet

To evaluate the predictive role of the circulating levels of vascular endothelial growth factor (VEGF) in gastric cancer patients. Materials and methods: This study is a case-control study. We measured serum VEGF levels of 30 patients aged between 34 and 83 years with gastric cancer and 30 patients without malignant pathology, operated on for benign pathologies, with ages ranging from 18 to 69. Results: Serum levels of VEGF were correlated with the tumor type classification (signet cell adenocarcinoma) and the presence of adjacent tissue invasion. There was also a positive correlation between serum VEGF and carcinoembryonic antigen levels. Conclusion: In gastric cancer patients, serum VEGF levels may provide additional prognostic information for preoperative evaluation of invasion and tumor type.

🔖

Cite This Article

BİLGİÇ, C. İ., TEZ, M. (2015). Serum VEGF levels in gastric cancer patients: correlation with clinicopathological parameters. Turkish Journal of Medical Sciences, Cilt: 45 - Sayı: 1, 112–117. https://ajindex.com/articles/204877

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69–90.
  2. Peng L, Zhan P, Zhou Y, Fang W, Zhao P, Zheng Y, Xu N. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in gastric cancer: a meta- analysis. Mol Biol Rep 2012; 39: 9473–9484. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27–31. 7. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18: 4–25. 8. Kut C, MacGabhann F, Popel AS. Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. Br J Cancer 2007; 97: 978–985.
  3. Jubb AM, Oates AJ, Holden S, Koeppen H. Predicting benefit from anti-angiogenic agents in malignancy. Nat Rev Cancer 2006; 6: 626–635.
  4. Green F, Page P, Fleming I. AJCC Cancer Staging Handbook. 6th ed. New York, NY, USA: Springer Verlag; 2002. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182–1186.
  5. Du JR, Jiang Y, Zhang YM, Fu H. Vascular endothelial growth factor and microvascular density in esophageal and gastric carcinomas. World J Gastroenterol 2003; 9: 1604–1606.
  6. Maeda K, Kang SM, Ogawa M, Onoda N, Sawada T, Nakata B, Kato Y, Chung YS, Sowa M. Combined analysis of vascular endothelial growth factor and platelet-derived endothelial cell growth factor expression in gastric carcinoma. Int J Cancer 1997; 74: 545–550.
  7. Saito H, Tsujitani S, Kondo A, Ikeguchi M, Maeta M, Kaibara N. Expression of vascular endothelial growth factor correlates with hematogenous recurrence in gastric carcinoma. Surgery 1999; 125: 195–201.
  8. Wang X, Chen X, Fang J, Yang C. Overexpression of both VEGF-A and VEGF-C in gastric cancer correlates with prognosis, and silencing of both is effective to inhibit cancer growth. Int J Clin Exp Pathol 2013; 6: 586–597.
  9. Dittrich C, Jakesz R, Havelec L, Lenzhofer R, Breyer S, Moser K. Carcinoembryonic antigen (CEA) plasma level determination in the management of gastric cancer patients. Cancer Detect Prev 1985; 8: 181–187.
  10. Gaspar MJ, Arribas I, Coca MC, Diez-Alonso M. Prognostic value of carcinoembryonic antigen, CA 19-9 and CA 72-4 in gastric carcinoma. Tumour Biol 2001; 22: 318–322.
  11. Ishigami S, Natsugoe S, Hokita S, Che X, Tokuda K, Nakajo A, Iwashige H, Tolcushige M, Watanabe T, Takao S et al. Clinical importance of preoperative carcinoembryonic antigen and carbohydrate antigen 19-9 levels in gastric cancer. J Clin Gastroenterol 2001; 32: 41